Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P10721
UPID:
KIT_HUMAN
Alternative names:
Piebald trait protein; Proto-oncogene c-Kit; Tyrosine-protein kinase Kit; p145 c-kit; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
Alternative UPACC:
P10721; B5A956; D5LXN2; D5M931; F5H8F8; Q6IQ28; Q99662; Q9UM99
Background:
The Mast/stem cell growth factor receptor Kit, known as c-Kit, plays a pivotal role in cell survival, proliferation, hematopoiesis, and melanogenesis. It acts as a receptor for KITLG/SCF, activating multiple signaling pathways, including AKT1, MAPK, and STAT family members, crucial for various cellular functions.
Therapeutic significance:
c-Kit's involvement in diseases like Piebald trait, Gastrointestinal stromal tumor, Testicular germ cell tumor, Acute myelogenous leukemia, and Mastocytosis underscores its therapeutic potential. Targeting c-Kit could lead to innovative treatments for these conditions.